Today’s BSX stock price saw mild gains at $73.90, driven by institutional repositioning. Boston Scientific’s strong cash flow positions it for strategic mergers that could expand market breadth. Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions. Boston Scientific’s stock has shown mixed performance during past market downturns, at times faring worse than the S&P 500. During the “Inflation Shock” of 2022, BSX stock experienced a 25.2% decline, aligning closely with the S&P 500’s 25.4% drop, and fully recovered by December 2022. The COVID-19 pandemic in 2020 saw a more significant impact, with BSX stock falling 43.5% compared to the S&P 500’s 33.9% decline, though it fully recovered by August 2021. The Global Financial Crisis of 2008 presented the most substantial challenge, with BSX stock plummeting 70.5% against the S&P 500’s 56.8% fall, and taking until November 2015 to fully recover. Trading sessions saw BSX stock price steady at $73.50, supported by a positive revision in industry-wide medtech forecasts. Investors continue to monitor innovation cycles for sustainable returns.